Cost-utility of pre-emptive plerixafor versus rescue plerixafor in the mobilization of hematopoietic stem cells in multiple myeloma

20260 citationsJournal Article

Authors

Tallys Kalynka Feldens · Universidade Tecnológica Federal do Paraná

Roselene Mesquita Augusto Passos · Universidade de São Paulo

Juliana de Oliveira Martins · Dr. Euryclides Hospital de Jesus Zerbini

Alessandro Gonçalves Campolina · Universidade de São Paulo

Cesar de Almeida Neto · Fundação Pró-Sangue Hemocentro de São Paulo

Abstract

Preemptive plerixafor passes the cost-utility guidelines to be used in MM patients in Brazil, potentially guiding policy decisions on resource allocation within the national health system.

Topics & Keywords

Hematopoietic Stem Cell Transplantation Multiple Myeloma Research and Treatments Acute Myeloid Leukemia Research

UN Sustainable Development Goals

Partnerships for the goals

Publication Details

Published in: Expert Review of Pharmacoeconomics & Outcomes Research

Volume 26, Issue 2, pp. 279-287

DOI: 10.1080/14737167.2026.2612985

Field-Weighted Citation Impact: 0.00